Macquarie Group LTD Puma Biotechnology, Inc. Transaction History
Macquarie Group LTD
- $79.1 Billion
- Q2 2025
A detailed history of Macquarie Group LTD transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 61,255 shares of PBYI stock, worth $335,677. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,255
Previous 61,255
-0.0%
Holding current value
$335,677
Previous $181,000
16.02%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PBYI
# of Institutions
125Shares Held
33.4MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$22.6 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$20.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$19.6 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$11 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$10.3 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $250M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...